scispace - formally typeset
Open AccessJournal ArticleDOI

Untimely Myocardial Infarction or COVID-19 Vaccine Side Effect

TLDR
The case of a 96-year-old female, with no known cardiac history, who suffered a myocardial infarction (MI) one hour after her first Moderna coronavirus disease 2019 (COVID-19) vaccination was presented in this paper.
Abstract
We present the case of a 96-year-old female, with no known cardiac history, who suffered a myocardial infarction (MI) one hour after her first Moderna coronavirus disease 2019 (COVID-19) vaccination. The patient was medically managed and discharged three days later. We are unable to attribute the cause of the patient's MI to the Moderna vaccine unless further data are published. As healthcare providers, we need to be aware of attempts to correlate bad outcomes with the vaccine without substantiated data, and anticipate patient questions that may arise from these reports. Any research on the topic should be written carefully and avoid overstating the findings. If more reports of serious side effects in older adults are published, providers should consider additional screenings prior to COVID-19 vaccination.

read more

Citations
More filters
Journal ArticleDOI

Clinical cardiovascular emergencies and the cellular basis of COVID-19 vaccination: from dream to reality?

TL;DR: The adverse cardiovascular responses resulting from COVID-19 vaccines have been tabulated in this article , with the majority of fatalities occurring among elderly patients (aged > 65 years) and the latter being more predominant in young adults following the second dose.
Journal ArticleDOI

Link between COVID-19 vaccines and myocardial infarction

TL;DR: Many studies linked MI to COVID-19 vaccinations, but no definitive association could be found.
Journal ArticleDOI

Acute Coronary Syndrome After Inactivated SARS-COV-2 Vaccine.

TL;DR: Two cases of patients presenting with chest pain, abnormal electrocardiography, and elevated troponin consistent with non-ST-elevation myocardial infarction within 24 hours after receiving the CoronaVac COVID-19 vaccine are presented.
Journal ArticleDOI

A comprehensive insight into current control of COVID-19: Immunogenicity, vaccination, and treatment.

TL;DR: In this paper , the authors reviewed the immunological response against SARS-CoV-2 and the vaccines approved by the World Health Organization (WHO) for COVID-19, their mechanisms, and side effects.
References
More filters
Journal ArticleDOI

The Burden of Cardiovascular Disease in the Elderly: Morbidity, Mortality, and Costs

TL;DR: An overview of the epidemiology of CVD in older adults is provided, including an assessment of the impact of CVC on mortality, morbidity, and health care costs.
Journal ArticleDOI

Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020

TL;DR: In this article, the clinical and epidemiologic characteristics of case reports of allergic reactions after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine during December 14-23, 2020, in the United States.
Journal Article

Prevalence of uncontrolled risk factors for cardiovascular disease: United States, 1999-2010.

TL;DR: The most recent prevalence estimates and trends of uncontrolled high blood pressure, uncontrolled high levels of low-density lipoproteins cholesterol (LDL-C), and current cigarette smoking among adults aged 20 and over are presented.
Journal ArticleDOI

Neurological Complications of COVID-19: Guillain-Barre Syndrome Following Pfizer COVID-19 Vaccine

TL;DR: Wang et al. as discussed by the authors reported a case of Guillain-Barre syndrome (GBS) after receiving the first dose of Pfizer - COVID-19 vaccine.
Journal ArticleDOI

Covid-19: Norway investigates 23 deaths in frail elderly patients after vaccination.

Ingrid Torjesen
- 15 Jan 2021 - 
TL;DR: For example, the Norwegian Medicines Agency (NOMA) investigated 13 of the deaths so far and concluded that common adverse reactions of mRNA vaccines, such as cancer, were not linked to the vaccine as discussed by the authors.
Related Papers (1)

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

Merryn Voysey, +81 more
- 09 Jan 2021 -